---
title: "Obefazimod (ABX464) in Ulcerative colitis: Care management intervention strategies"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Care management intervention strategies. Topics: Treat-to-target with endoscopic improvement and fecal calprotectin: ACG 2025; Monitoring schedule after starting advanced therapy: AGA 2024; Treat-to-target, escalation, and multidisciplinary care: ECCO 2026; Therapeutic drug monitoring; 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Treat-to-target with endoscopic improvement and fecal calprotectin: ACG 2025

> “We recommend treating patients with UC to achieve endoscopic improvement (defined as resolution of inflammatory changes [MES 0 or 1]) to increase the likelihood of sustained steroid-free remission and to prevent hospitalizations and surgery (Strong recommendation, moderate quality of evidence).”
> “We recommend the use of FC in UC to assess response to therapy, to evaluate suspected relapse, and during maintenance (Strong recommendation, moderate quality of evidence).”
> “As mentioned in the prior section on Goals of Management, any treatment that is selected and administered to a patient with UC should be assessed at a defined time point (6–12 weeks) to confirm its efficacy and safety, and given risk of losing response to therapy over time, a disease monitoring strategy should be incorporated, with the intention of identifying secondary nonresponse (loss of response) early and to allow subsequent adjustment in treatment to prevent complications and additional morbidity.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.4-2"></a>

### Monitoring schedule after starting advanced therapy: AGA 2024

> “Initiation of advanced therapy should be followed by monitoring for symptomatic response within 3 months of initiation, symptomatic and biochemical remission within 3–6 months, and endoscopic improvement/ remission within 6–12 months.”
> “On-treatment monitoring for potential toxicity from immunosuppressive therapies, such as periodic monitoring of hemogram, chemistries and transaminases, should be performed, according to drug label.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.4-3"></a>

### Treat-to-target, escalation, and multidisciplinary care: ECCO 2026

> “describes an approach in which a treatment goal is set and agreed upon following discussions between individual patients and treating clinicians, and which is to be achieved within a defined period.”
> “Until then, treat-to-target beyond steroid-free clinical remission remains a promising but not yet conclusively validated framework.”
> “In patients on either conventional or advanced therapies, the presence of both active symptoms [such as increased liquid stool frequency, rectal bleeding, and often bowel urgency] and either biomarker or endoscopic evidence of inflammation should prompt action.”
> “A multidisciplinary team approach is an important element of inflammatory bowel disease care, helping to coordinate and personalize the management of complex cases. Regular multidisciplinary team meetings assist shared decision-making, reduce variation in practice, and contribute to improved outcomes and service governance [Agreement: 98%]”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.4-4"></a>

### Therapeutic drug monitoring

> “In patients with moderately to severely active UC who are responders to anti-TNF therapy and now losing response, we suggest measuring serum drug levels and antidrug antibodies (if there is not sufficient drug present) to assess reason for loss of response (Conditional recommendation, very low quality of evidence).”
> “There is insufficient evidence to recommend assessment of serum concentrations of vedolizumab, ustekinumab, guselkumab, mirikizumab, or risankizumab.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “There are insufficient data to support proactive therapeutic drug monitoring with anti-tumor necrosis factor agents, vedolizumab, or ustekinumab in the management of ulcerative colitis. We suggest reactive therapeutic drug monitoring in patients with loss of response to an anti-tumor necrosis factor agent to guide the treatment strategy [Agreement: 92%]”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.4-5"></a>

### Payer utilization management: ACG 2025 position

> “These strategies include step therapy requirements, denials of recommended treatments in favor of alternative advanced therapy options, increased copayment requirements, and frequent reauthorization practices. Insurance companies have also denied coverage for needed monitoring and drug-related assessments such as FC and serum concentrations of anti-TNF therapies.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.4-6"></a>

### Pre-treatment screening required by labels of oral advanced therapies

> “Test for latent TB before and during therapy; treat latent TB prior to use.”

Source: [Xeljanz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf)

> “Obtain an electrocardiogram (ECG) to assess for preexisting cardiac conduction abnormalities before starting treatment.”

Source: [Velsipity prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216956s002lbl.pdf)

<a id="topic-2.2.2.4-7"></a>

### Obefazimod-specific care management program

No evidence found.

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
